Abeona Therapeutics (NASDAQ:ABEO) & Celsion (NASDAQ:CLSN) Head to Head Contrast

Abeona Therapeutics (NASDAQ:ABEO) and Celsion (NASDAQ:CLSN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Earnings & Valuation

This table compares Abeona Therapeutics and Celsion’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $3.00 million 38.14 -$56.67 million ($1.19) -1.95
Celsion $500,000.00 54.12 -$11.88 million ($0.68) -1.81

Celsion has lower revenue, but higher earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abeona Therapeutics and Celsion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics N/A -64.62% -46.40%
Celsion -1,489.20% -53.40% -23.03%

Analyst Recommendations

This is a summary of recent ratings for Abeona Therapeutics and Celsion, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics 0 3 2 0 2.40
Celsion 0 0 2 0 3.00

Abeona Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 589.66%. Celsion has a consensus target price of $0.00, suggesting a potential downside of 100.00%. Given Abeona Therapeutics’ higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Celsion.

Risk & Volatility

Abeona Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, Celsion has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Institutional & Insider Ownership

59.4% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Celsion shares are owned by institutional investors. 33.6% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Celsion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Celsion beats Abeona Therapeutics on 7 of the 13 factors compared between the two stocks.

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.